

ASX Release

Issued 14 January 2022

Appendix 3Y – Corrections

Sigma Healthcare Limited (ASX:SIG) advises that:

- (a) the first attached Appendix 3Y – Change in Director’s Interest Notice replaces the notice for Mr Michael Sammells lodged with the ASX on 5 October 2021. The previously lodged Appendix 3Y inadvertently included incorrect details with regard to the number of fully paid ordinary shares held by Mr Sammells. A corrected Appendix 3Y for Mr Sammells is attached; and
- (b) the second attached Appendix 3Y – Change in Director’s Interest Notice replaces the notice for Mr Michael Sammells lodged with the ASX on 29 December 2021. The previously lodged Appendix 3Y inadvertently included incorrect details with regard to the number of fully paid ordinary shares held by Mr Sammells (as a result of carrying across the inadvertent incorrect details from the Appendix 3Y lodged with the ASX on 5 October 2021). A corrected Appendix 3Y for Mr Sammells is also attached.

This announcement is authorised by order of the Board

For more information, please contact:

Kara McGowan
General Counsel & Company Secretary
Kara.McGowan@sigmahealthcare.com.au
+61 498 759 639

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael SAMMELLS
Date of last notice	06/07/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	30/09/2021
No. of securities held prior to change	52,876 Direct - 52,876
Class	FPO
Number acquired	9,678
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$6,000.36
No. of securities held after change	62,554 Direct- 62,554

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares purchased under NED's Share Plan
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA HEALTHCARE LIMITED
ABN	ABN 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael SAMMELLS
Date of last notice	30/09/2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	22/12/2021
No. of securities held prior to change	62,554 Direct - 62,554
Class	FPO
Number acquired	12,431
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,524.34
No. of securities held after change	74,985 Direct - 74,985

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares Purchased under NED's Share Plan
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.